Phase I safety and pharmacokinetic study of magnesium isoglycyrrhizinate after single and multiple intravenous doses in chinese healthy volunteers

Journal of Clinical Pharmacology

Volumn 47, Issue 6, 2007, Pages 767-773

  Sun, Li ^a   Shen, Jinfang ^a   Pang, Xiaoyun ^a   Lu, Lungen ^a   Mao, Yimin ^a   Zeng, Minde ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Magnesium isoglycyrrhizinate; Multiple dose; Pharmacokinetics; Safety; Single dose

Indexed keywords

MAGNESIUM ISOGLYCYRRHIZINATE; SAPONIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; LIVER DYSFUNCTION; MALE; MULTIPLE DRUG DOSE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; SINGLE DRUG DOSE;

ADULT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; SAPONINS; TRITERPENES;

EID: 34249025670     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007299757     Document Type: Article

References (17)

1. Xing GX, Li N., Wang T., Yao MY Advances in studies on flavonoids of licorice [in Chinese]. Zhongguo Zhong Yao Za Zhi. 2003 ; 28: 593-597.
2. Ven Rossum TG, Vulto AG, de Man RA, Brouwer JT, Schalm SW Glycyrrhizin as potential treatment for chronic hepatitis C. Aliment Pharmacol Ther. 1998 ; 12: 199-205.
3. Guo H., Huang AL, Yao YO, Tang N., Zhang DF The effect of diammonium glycyrrhizinate to prevent liver cell apoptosis induced by endotoxins [in Chinese]. Zhonghua Gan Zang Bing Za Zhi. 2004 ; 12: 159-162.
4. Cai Y., Shen XZ, Wang JY Effects of glycyrrhizin on genes expression during the process of liver fibrosis [in Chinese]. Zhonghua Yi Xue Za Zhi. 2003 ; 83: 1122-1125.
5. Watanabe M., Uchida Y., Sato S., et al. Report of a case showing a recovery from liver cirrhosis to chronic hepatitis, type C, after glycyrrhizin injection for 2 years and a sustained response by the following interferon therapy. Am J Gastroenterol. 2001 ; 96: 1947-1949.
6. Fujisawa Y., Sakamoto M., Matsushita M., Fujita T., Nishioka K. Glycyrrhizin inhibits the lytic pathway of complement-possible mechanism of its anti-inflammatory effect on liver cells in viral hepatitis. Microbiol Immunol. 2000 ; 44: 799-804.
7. Sasaki H., Takei M., Kobayashi M., Pollard RB, Suzuki F. Effect of glycyrrhizin, an active component of licorice roots, on HIV replication in cultures of peripheral blood mononuclear cells from HIV-seropositive patients. Pathobiology. 2002 ; 70: 229-236.
8. Hu Q., Ding J., Liu S., Li P., Hu G. Pharmacokinetics of magnesium glycyrrhizinate following intravenous administration of magnesium glycyrrhizinate in rats. Eur J Drug Metab Pharmacokinet. 2003 ; 28: 259-264.
9. Van Rossum TG, Vulto AG, Hop WC, Brouwer JT, Niesters HG, Schalm SW Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase 1/2 trail. J Gastroenterol Hepatol. 1999 ; 14: 1093-1099.
10. Arase Y., Ikeda K., Murashima N., et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer. 1997 ; 79: 1494-1500.
11. Schalm SW, Van Rossum Tgj. Goals of antiviral therapy: viral clearance or ALT normalization. Hepatol Clin. 1998 ; 6 (suppl 1). 85-91.
12. Ichikawa T., Ishida S., Sakiya Y., Sawada Y., Hanano M. Biliary excretion and enterohepatic cycling of glycyrrhizin in rats. J Pharm Sci. 1986 ; 75: 672-675.
13. Ishida S., Sakiya Y., Ichikawa T., Taira Z., Awazu S. Prediction of glycyrrhizin disposition in rat and man by a physiologically based pharmacokinetic model. Chem Pharm Bull. 1990 ; 38: 212-218.
14. Krahenbuhl S., Hasler F., Krapf R. Analysis and pharmacokinetics of glycyrrhizic acid and glycyrrhinic acid in human and experimental animals. Steroids. 1994 ; 59: 121-126.
15. Yamamura Y., Kawakami J., Santa T., et al. Pharmacokinetic profile of glycyrrhizin in healthy volunteers by a new high-performance liquid chromatographic method. J Pharm Sci. 1992 ; 81: 1042-1046.
16. Tanaka N., Yamamura Y., Santa T., et al. Pharmacokinetic profiles of glycyrrhizin in patients with chronic hepatitis. Biopharm Drug Dispos. 1993 ; 14: 609-614.
17. Yamamura Y., Tamaka N., Santa T., et al. The relationship between pharmacokinetic behaviour of glycyrrhizin and hepatic function in patients with acute hepatitis and liver cirrhosis. Biopharm Drug Dispos. 1995 ; 16: 13-21.